Arbutus Biopharma (ABUS) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OmniAb (OABI) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 176.4% versus a gain of 0.0%. Over five years, ABUS leads with a +5.1% price change compared with -54.3% for OABI. OmniAb is the larger company by market cap ($677.5 million vs $640.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | OABI |
|---|---|---|
| Share price | $4.18 | $4.66 |
| Market cap | $640.69M | $677.52M |
| 1-day change | -2.56% | +2.19% |
| YTD return | -10.81% | +146.49% |
| 1-year return | 0.00% | +176.36% |
| 5-year return | +5.15% | -54.26% |
| P/E ratio (TTM) | 5.29 | — |
| EPS (TTM) | $0.79 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $5.43 |
| 52-week low | $3.50 | $1.30 |
| Distance from 52-week high | -23.30% | -14.18% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +27.99% | +88.84% |
| Average volume | 4.68M | 1.45M |
| Shares outstanding | 153.28M | 145.39M |
| Employees | 19 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed ABUS by 176.4 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
ABUS vs OABI FAQ
Which is bigger, Arbutus Biopharma or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $677.52M compared with $640.69M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or OABI?
OABI returned +176.36% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arbutus Biopharma and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.